3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Completed
1
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Breast Neoplasms
8
Neoplasms
4
Multiple Myeloma
3
Radiation Injuries
2
Multiple Chronic Conditions
2
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
2
Leukemia, Lymphocytic, Chronic, B-Cell
2
Esophageal Neoplasms
2
Cognitive Dysfunction
2
Brain Neoplasms
2
Substance-Related Disorders
1
Sarcoma
1
Rectal Neoplasms
1
Prostatic Neoplasms
1
Pathologic Complete Response
1
Pain
1
Osteosarcoma
1
Neoplasms, Second Primary
1
Neoplasms, Plasma Cell
1
Nasopharyngeal Neoplasms
1
Nasopharyngeal Carcinoma
1
Mobility Limitation
1
Melanoma
1
Lymphoma, B-Cell, Marginal Zone
1
Lymphoma
1
Leukemia
1
Kidney Neoplasms
1
Hyperthermia
1
Hematologic Neoplasms
1
Head and Neck Neoplasms
1
Interventions
Docetaxel
171
Radiotherapy
144
Magnetic Resonance Spectroscopy
142
Leuprolide
112
Prednisone
108
enzalutamide
102
Radiosurgery
101
Abiraterone Acetate
94
Androgen Antagonists
91
Goserelin
83
bicalutamide
81
gallium 68 PSMA-11
70
Surveys and Questionnaires
63
apalutamide
57
Specimen Handling
56
acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide
55
Radiation
47
Gonadotropin-Releasing Hormone
45
Standard of Care
44
Biopsy
44
Brachytherapy
42
Radiotherapy, Intensity-Modulated
40
Blood Specimen Collection
40
darolutamide
39
abiraterone
39
cabazitaxel
35
Exercise
35
Carboplatin
33
Pluvicto
32
Triptorelin Pamoate
31
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Prostatic Neoplasms
×
Patient Reported Outcome Measures
×
Clear all
NCT04638049
2022-12-01
IMPRINT
University Hospital, Ghent
Phase NA
Completed
50 enrolled